Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 11/20 | 0.41 |
| ▸ | FYN | P06241 | 4/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262262 | 0.95 | MAPKAPK2 (0.40) | MAPKAPK2FYNCDK4CCNA2CDK2 | |
| SCHEMBL4265876 | 0.90 | MAPKAPK2 (0.41) | MAPKAPK2CDK4CCNA2CDK2CCND3 | |
| SCHEMBL1660776 | 0.86 | MAPKAPK2 (0.43) | MAPKAPK2FYNCDK2 | |
| SCHEMBL4264450 | 0.85 | MAPKAPK2 (0.45) | MAPKAPK2 | |
| SCHEMBL6794024 | 0.84 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL6799047 | 0.81 | PARP10 (0.47) | MAPKAPK2RIPK3 | |
| SCHEMBL4260865 | 0.81 | MAPKAPK2 (0.41) | MAPKAPK2 | |
| SCHEMBL4264409 | 0.80 | MAPKAPK2 (0.56) | MAPKAPK2 | |
| SCHEMBL4258866 | 0.79 | TMEM97 (0.44) | MAPKAPK2FYN | |
| SCHEMBL6792722 | 0.79 | MAPKAPK2 (0.44) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885FYN 441/4885CDK4 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.